Journal Article

New pitfall for the pharmaceutical industry

Maria Isabel Manley and Anna Wray

in Journal of Intellectual Property Law & Practice

Volume 1, issue 4, pages 266-271
Published in print March 2006 | ISSN: 1747-1532
Published online January 2006 | e-ISSN: 1747-1540 | DOI: http://dx.doi.org/10.1093/jiplp/jpl003
New pitfall for the pharmaceutical industry

More Like This

Show all results sharing these subjects:

  • Arbitration
  • Intellectual Property Law

GO

Show Summary Details

Preview

Legal context This article reviews the Commission decision that fined AstraZeneca €60 million for abuse of Article 82 EC. It looks at the decision in the context of the EU legal framework for pharmaceuticals and considers the legal basis for the Commission decision.

Key points The article highlights the key points of the alleged abusive practices that do not appear to be consistent with the EU regulatory legal framework and the ECJ jurisprudence in particular, read in conjunction with the principle of commercial freedom.

Practical significance The Commission decision (if upheld by the courts) would have an significant impact on the way that pharmaceutical companies run their business. This would constitute an unprecedented interference with the principle of commercial freedom afforded to pharmaceutical companies and specifically recognised by the ECJ.

Journal Article.  3865 words. 

Subjects: Arbitration ; Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.